Theravance 8-K 1-10-2006


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 

 
FORM 8-K
 


Current Report Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event Reported): January 10, 2006
 

 
THERAVANCE, INC.
(Exact Name of Registrant as Specified in its Charter)
 


Delaware
 
000-30319
 
94-3265960
(State or Other Jurisdiction of Incorporation)
 
(Commission File Number)
 
(I.R.S. Employer Identification Number)

901 Gateway Boulevard
South San Francisco, California 94080
(650) 808-6000
(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)
 


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 



 
Item 8.01 Other Events.
 
On January 10, 2006 Theravance, Inc. issued a press release relating to its Beyond Advair collaboration with GlaxoSmithKline. A copy of the news release is filed as Exhibit 99.1 to this report and is incorporated herein by reference.
 


ITEM 9.01 Financial Statements and Exhibits.
 
 
(c)
Exhibits
 
Exhibit
 
Description
     
Exhibit 99.1
 
Press Release dated January 10, 2006
 


SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
   
THERAVANCE, INC.
 
         
Date: January 10, 2006
 
By: 
/s/ Bradford J. Shafer
 
     
 
     
Bradford J. Shafer
 
     
Senior Vice President and General Counsel
 
 


EXHIBIT INDEX
 
Exhibit No.
 
Exhibit
             99.1
 
Press Release dated January 10, 2006